ArticleJournal of gynecologic oncology2022

Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database.

Akihiko Ueda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.